Research
Mixed
Endoscopic Sleeve Gastroplasty (ESG) is a highly cost-effective, less invasive alternative to surgery for Class I obesity, with an ICER well below willingness-to-pay thresholds.
For Class I obesity, ESG offers a durable, cost-effective alternative to surgery with a favorable safety profile. It is particularly valuable for patients who want more than lifestyle changes but are not candidates for or willing to undergo surgery.
GoodSupportsHIGH confidence
ESG, a less invasive endoscopic procedure, yields around 15% weight loss and has demonstrated favorable cost-effectiveness, particularly in class I obesity.
Why this rating
Based on multiple economic modeling studies (US, UK) showing favorable ICERs.
Source
Cost-Effectiveness of Obesity Treatments: Glucagon-Like Peptide-1 Receptor Agonists, Endoscopic Sleeve Gastroplasty, and Metabolic/Bariatric Surgery
Yeon‐Ju Huh · Journal of Metabolic and Bariatric Surgery · 2025
narrative_reviewCited 4×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →